RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
  Dementia
   Alzheimer's
  Parkinson's
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Alzheimer's Channel

subscribe to Alzheimer's newsletter
Latest Research : Aging : Dementia : Alzheimer's

   EMAIL   |   PRINT
Three molecules may be developed into new Alzheimer's drugs

Jul 23, 2005 - 1:16:00 AM
"The insights gained about the mechanisms of the molecular and genetic basis of the disease are beginning to add up and can be harnessed for treatments."

 
[RxPG] A team of scientists has discovered three molecules –– from a search of 58,000 compounds –– that appear to inhibit a key perpetrator of Alzheimer's disease.

Each of the three molecules protects the protein called "tau," which becomes hopelessly tangled in the brains of patients with Alzheimer's. The finding is promising news for the development of drugs for the disease.

Ken Kosik, co-director of the Neuroscience Research Institute at the University of California, Santa Barbara, headed the effort to find these molecules. The results of the study are published in the July issue of the journal Chemistry and Biology, released on Friday, July 22.

As baby boomers grow older, the incidence of Alzheimer's, already increasing, will rise much more. "Our approaches to the disease are flagrantly inadequate," said Kosik.

"There are a couple of FDA-approved drugs that help a little, but don't modify the disease. They give a little bit of symptomatic relief, but don't change the inexorable progression of the disease."

He said that new insights made over the past decade help to understand the molecular and genetic basis of the disease and these can now be built upon for the development of treatments. "There is no doubt that we need new approaches," said Kosik. "The insights gained about the mechanisms of the molecular and genetic basis of the disease are beginning to add up and can be harnessed for treatments."

Alzheimer's involves a complicated, interwoven series of regulatory steps of genes and proteins "talking" to each other, he explained. "When the conversation goes awry the disease process begins. And it is not just one gene or one protein causing the damage."

The complexity of Alzheimer's means that several different medications will likely be needed to control it, said Kosik. The same is true for many other diseases –– from AIDS to cancer. "It is likely that we will need to strategically target different aspects of the disease and put them together."

Kosik and his team chose to focus on the neurofibrillary tangles of neurons in the brain that, along with senile plaques, characterize Alzheimer's disease. The tangles are made of "tau," a protein that is also present normally in the brain.

"Tau goes wrong and becomes pathological when it becomes intensely phosphorylated," said Kosik. "This means that many phosphate groups attach to tau--modify it--and cause it to become dysfunctional."

The culprit is an enzyme, called CDK5, that attaches the phosphate to the tau protein, facilitating the disease process. The researchers set out to find a way to inhibit this enzyme, to keep it from putting any phosphate on tau.

In the laboratory, they purified the enzyme and purified tau protein, and watched tau get phosphorylated by the enzyme. They then performed a library search of small molecules (58,000 of them) in an attempt to find those that would prevent phosphorylation. Small molecules are preferred because they are more easily used as a drug since they can get through the body and into cells. It is also important to find molecules that will cross the blood brain barrier.

They then set up a test of nearly 400 small molecules that fit their criteria. The test results showed three small molecules that can inhibit the enzyme. These are candidates for development as drugs.

Kosik explained that proteins are strings of amino acids folded into small globs. All proteins that happen to be an enzyme involved in phosphorylation have one thing in common. They have a pocket that is almost always in the same place and this is where the phosphate attaches to the enzyme, in this case CDK5. To get a molecule that specifically prevents the enzyme from binding at the pocket is difficult.

Of the three compounds that the research group found, the scientists were able to locate where they bind. They found that one binds in the pocket, another binds at the edge of the pocket, and a third appears to bind completely outside the pocket. The scientists are most interested in the second and third compounds.

"This is the first demonstration that we can find small molecules that can more specifically affect the phosphorylation of tau by CDK5," said Kosik.

In terms of future directions, Kosik said, "There is lots to do here, lab testing, testing in animals, etc. But we have made an important step forward toward developing treatments for this disease."

He noted that this work is of a type usually performed by pharmaceutical companies, but in this case was completed in an academic environment.



Publication: July issue of the journal Chemistry and Biology
On the web: http://www.ucsb.edu/ 

Advertise in this space for $10 per month. Contact us today.


Related Alzheimer's News


Subscribe to Alzheimer's Newsletter

Enter your email address:


 Additional information about the news article
The work was partly funded by NIH grants, the Institute for the Study of Aging, and the Department of Energy Computational Science Graduate Fellowship.

In addition to Kosik, authors of the paper include: Jae Suk Ahn, Sungwoon Choi, and Gregory D. Cuny of the Department of Neurology and Laboratory for Drug Discovery in Neuroegeneration of Brigham and Women's Hospital, Harvard Medical School; Mala L. Radhakrishnan of the Computer Science and Artificial Intelligence Laboratory, Department of Chemistry, Massachusetts Institute of Technology; Marina Mapelli and Andrea Musacchio of the Structural Biology Unit of the Department of Experimental Oncology, European Institute of Oncology, Milan, Italy; Bruce Tidor of the Computer Science and Artificial Intelligence Laboratory, Biological Engineering Division, Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology.
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)